INTENSITY THERAPEUTICS, INC. (INTS) Form 8-K — Aug 11, 2026
Intensity Therapeutics reported a Q2 2026 net loss of $3.0 million versus $2.5 million a year ago and ended June 30, 2026 with $9.5 million in cash. The loss-per-share comparison ($1.11 vs $3.36) is flattered by a sharply higher share count, with weighted average shares up to 2.7 million from 755 thousand a year earlier. On the clinical side, the company has initiated activities to resume enrollment at a limited number of U.S. sites in its Phase 3 INVINCIBLE-3 soft tissue sarcoma study by Q3 2026, using an FDA-reviewed amended protocol.
Key figures
- Cash Position
- 9500000
- Atm facility size
- 60000000
- Q2 2026 ga expense
- 1251000
- Q2 2026 rd expense
- 1833000
- Pcr rate soc cohort b
- 42%
- Atm net proceeds post q2
- 1300000
- Atm net proceeds q2 2026
- 1600000
- Pcr rate int2306 cohort a
- 71%
- Weighted avg shares q2 2025
- 754725
- Weighted avg shares q2 2026
- 2706607
- Invincible4 enrollment target
- complete enrollment by end of 2027
- Grade3 adverse event reduction
- 44%
- Invincible4 preliminary data patients
- 14
- Invincible3 patients enrolled at pause
- 21
Price after filing
Close on the filing date to close N calendar days later (from $4.16). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.